A few of the attendees include Allergan Inc. (AGN),Amgen Inc. (AMGN), Boston Scientific Corp. (BSX), CVS Caremark Corp. (CVS), Helicos BioSciences Corp. (HLCS), Merck & Co., Inc. (MRK), UnitedHealth Group, Inc. (UNH) so you can see it appears to be a quite diversified group.
With the current economy and prospects few far between of any IPOs, the meeting in San Francisco might not be too upscale this year, although if you take a look at another source, you can see VC money is still flowing, but not in the amounts and fashions of what we have seen in the past. Blue Cross who is on the list has already established a VC fund and perhaps they are looking for investments.
Some companies only have perhaps 6 months left of financing while others may have only a year. One thing certainly appears to be a factor is the risk seems to be higher than in years past as well, much due to the new stance of the FDA and also due to the R and D changes in the way a new drug is brought to market as well, genomics has changed the picture quite a bit in that area.
Just like everywhere else in life there’s more information to be digested, more queries and algorithms to be created and run, thus the filtering and intelligent interpretation process moves in a heavily deluged bank of available information where there is very little room for errors or omission of information. BD
Tomorrow starts the most important healthcare investment conference of the year, The 27th Annual JP Morgan Healthcare Conference. While we won’t be in attendance, we’ll be providing updates throughout the day. The conference goes from Monday to Thursday with over 300 public (mainly small to mid cap) healthcare companies presenting. With the economy in the crapper, this year’s conference should prove to be an interesting one as investors retreat from the public markets and companies find themselves strapped for cash.
0 comments :
Post a Comment